axcella has pioneered a new therapeutic class – defined amino acid compositions (daacs™). our daac therapeutics leverage the essential signaling function of amino acids to restore health across a network of dysregulated pathways, and provide safer solutions for patients with complex disease. with our axcellerator™ platform, we are transforming traditional drug discovery and development by generating patient data in less than a year from indication selection. this platform has delivered a rich pipeline including clinical programs in liver, metabolic, cns and orphan diseases.
Company profile
Ticker
AXLA
Exchange
Website
CEO
William R. Hinshaw
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Pronutria Biosciences, Inc.
SEC CIK
Corporate docs
Subsidiaries
Acora Nutrition LLC • Axcella Health Securities Corporation ...
AXLA stock data
Latest filings (excl ownership)
25-NSE
Exchange delisting
15 Feb 24
8-K
Regulation FD Disclosure
22 Dec 23
8-K
Completion of Acquisition or Disposition of Assets
19 Dec 23
8-K
Submission of Matters to a Vote of Security Holders
4 Dec 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
17 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
17 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
17 Nov 23
DEF 14A
Definitive proxy
17 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
9 Nov 23
PRE 14A
Preliminary proxy
6 Nov 23
Transcripts
AXLA
Earnings call transcript
2022 Q3
1 Nov 22
AXLA
Earnings call transcript
2021 Q4
30 Mar 22
AXLA
Earnings call transcript
2021 Q2
31 Jul 21
AXLA
Earnings call transcript
2021 Q1
9 May 21
AXLA
Earnings call transcript
2020 Q4
17 Mar 21
AXLA
Earnings call transcript
2020 Q3
12 Nov 20
AXLA
Earnings call transcript
2020 Q2
10 Aug 20
Latest ownership filings
SC 13G/A
FMR LLC
11 Sep 23
4
Margaret Koziel
3 Mar 23
4
Margaret Koziel
24 Feb 23
4
William Hinshaw
24 Feb 23
4
Paul Fehlner
24 Feb 23
SC 13G/A
HarbourVest Partners L.P.
14 Feb 23
4
Paul Fehlner
13 Feb 23
SC 13G/A
FMR LLC
9 Feb 23
SC 13G/A
Societe des Produits Nestle S.A.
2 Feb 23
4
TORBEN STRAIGHT NISSEN
18 Nov 22
Financial summary
Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 8.88 mm | 8.88 mm | 8.88 mm | 8.88 mm | 8.88 mm | 8.88 mm |
Cash burn (monthly) | 1.22 mm | 2.10 mm | 1.18 mm | 3.81 mm | 2.93 mm | 4.00 mm |
Cash used (since last report) | 10.92 mm | 18.81 mm | 10.58 mm | 34.17 mm | 26.28 mm | 35.81 mm |
Cash remaining | -2.03 mm | -9.93 mm | -1.70 mm | -25.29 mm | -17.40 mm | -26.93 mm |
Runway (months of cash) | -1.7 | -4.7 | -1.4 | -6.6 | -5.9 | -6.7 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 32 |
Opened positions | 5 |
Closed positions | 4 |
Increased positions | 1 |
Reduced positions | 9 |
13F shares | Current |
---|---|
Total value | 10.47 bn |
Total shares | 83.39 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Flagship Pioneering | 29.25 mm | $6.39 bn |
Flagship VentureLabs IV | 18.14 mm | $29.39 mm |
Societe des Produits Nestle | 11.11 mm | $0.00 |
FMR | 10.27 mm | $2.24 bn |
Harbourvest Partners | 6.21 mm | $1.36 bn |
HarbourVest Partners | 6.21 mm | $0.00 |
Vanguard | 823.43 k | $179.76 mm |
Geode Capital Management | 338.31 k | $73.85 mm |
BLK Blackrock | 247.92 k | $54.12 mm |
Bridgeway Capital Management | 200.41 k | $43.75 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Mar 23 | Margaret Koziel | Common Stock | Sell | Dispose S | No | Yes | 0.58 | 679 | 393.82 | 24,883 |
17 Feb 23 | William Hinshaw | Stock Option Common Stock | Grant | Acquire A | No | No | 0.6759 | 275,000 | 185.87 k | 275,000 |
17 Feb 23 | Paul Fehlner | Stock Option Common Stock | Grant | Acquire A | No | No | 0.6759 | 70,000 | 47.31 k | 70,000 |
17 Feb 23 | Margaret Koziel | Stock Option Common Stock | Grant | Acquire A | No | No | 0.6759 | 70,000 | 47.31 k | 70,000 |
10 Feb 23 | Paul Fehlner | Common Stock | Sell | Acquire S | No | Yes | 0.6602 | 5,221 | 3.45 k | 58,081 |